Eli Lilly and Company (LLY)

Over the past six months, Eli Lilly's stock price has experienced fluctuations, with a share price of $771.71 as of July 18, 2025, representing a decline of 10.88% from July 22, 2024, but showing a modest change of 0.01% and a 3.19% increase over the last six months. Key events impacting the stock include strong demand for weight-loss drugs, Q4 2024 earnings and guidance, FDA approvals and label updates, acquisition activity, analyst downgrades, and concerns over drug pricing reforms and competition.

While detailed information on demand seasonality for all of Eli Lilly's products is limited, there are some insights. There was a suggestion that seasonality might be at play regarding the growth of GLP-1 drug demand. The demand for pharmaceutical products, especially those treating chronic conditions, tends to be relatively stable throughout the year. Historically, July has shown a chance of being a "green month" for LLY stock performance.

Eli Lilly and Company is a global pharmaceutical company founded in 1876, focusing on the discovery, development, manufacturing, and marketing of human healthcare products, particularly biopharmaceuticals and pharmaceuticals. Their mission is to improve lives worldwide through medicines, covering therapeutic areas like cardiometabolic health, oncology, immunology, and neuroscience. Key products include Mounjaro, Zepbound, Trulicity, Jardiance, Humalog, Humulin, Basaglar, Verzenio, Alimta, Taltz, Olumiant, Cymbalta, Zyprexa, Kisunla, Cialis, and Prozac.

Eli Lilly has a significant global presence with offices in 18 countries, R&D facilities in 7-8 countries, and manufacturing in 9 countries. Its products are sold in approximately 110-125 countries worldwide. The United States is its largest market, accounting for approximately 67.44% of its total revenue in fiscal year 2024, with other significant regions including Europe, Japan, and China.

Eli Lilly's brand reputation has seen positive developments due to the success of Mounjaro and Zepbound, with its brand value soaring by 53% to nearly $6 billion. However, the company faces scrutiny regarding access to medicine, ranking lower in technical areas in the 2024 Access to Medicine Index. Eli Lilly launched the next phase of its "Get Better" corporate branding campaign, focusing on challenging misperceptions about obesity care. A report from April 2024 indicated a high level of reputation risk for Eli Lilly over the past year.

Eli Lilly and Company's ownership is primarily institutional, with 5,566 institutional owners and shareholders holding over 939 million shares, collectively owning over 50% of the company. Major institutional owners include PNC Financial Services Group, Inc., Lilly Endowment Inc., Vanguard Group Inc., and BlackRock, Inc. Individual investors hold approximately 12% to 37.57% of the stock, while insiders own under 1% to 10.30%.